NCT04013880View on ClinicalTrials.gov

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 27, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2022

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
Interventions
DRUG

CDA Inhibitor E7727/Decitabine Combination Agent ASTX727

Given by mouth

DRUG

IDH-1 Inhibitor FT-2102

Given by mouth

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Forma Therapeutics, Inc.

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER